{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05075577",
            "orgStudyIdInfo": {
                "id": "EPI-7386-CS-010"
            },
            "organization": {
                "fullName": "ESSA Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC",
            "officialTitle": "A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "epi-in-combination-with-enzalutamide-compared-with-enzalutamide-alone-in-subjects-with-mcrpc"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-09-14",
            "studyFirstSubmitQcDate": "2021-10-07",
            "studyFirstPostDateStruct": {
                "date": "2021-10-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "ESSA Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1/2 study of EPI-7386 orally administered in combination with enzalutamide in subjects with mCRPC.\n\nPhase 1 of the study will be a single-arm dose escalation study of EPI-7386 in combination with a fixed dose of enzalutamide. This portion of the study will primarily evaluate the safety and tolerability of the drug combination and establish the RP2CDs for EPI-7386 and enzalutamide when dosed in combination. In addition, blood sampling will be conducted for PK evaluation to assess the potential DDI between the two drugs.\n\nOnce the RP2CD for each drug has been established, Phase 2 of the study will commence. Phase 2 is a two-arm, randomized (2:1), open-label study. Approximately 120 subjects will be randomized 2:1 to:\n\n* Group 1: EPI-7386 at the RP2CD + enzalutamide(depending on the results of the Phase 1) (n=80)\n* Group 2: Enzalutamide single agent (n=40) The planned dose of enzalutamide and EPI-7386 for the combination arm will be those determined in the Phase 1 of this study based on safety and exposure data. Subjects may remain on study treatment as long as they are tolerating treatment without disease progression based on RECIST v1.1 and/or PCWG3."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1 Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "600 mg QD EPI-7386 in combination of Enzalutamide120 mg",
                    "interventionNames": [
                        "Drug: EPI-7386 with Enzalutamide"
                    ]
                },
                {
                    "label": "Phase 1 Cohort 2",
                    "type": "EXPERIMENTAL",
                    "description": "800 mg QD EPI-7386 in combination of Enzalutamide120 mg",
                    "interventionNames": [
                        "Drug: EPI-7386 with Enzalutamide"
                    ]
                },
                {
                    "label": "Phase 1 Cohort 3",
                    "type": "EXPERIMENTAL",
                    "description": "600 mg BID EPI-7386 in combination of Enzalutamide120 mg",
                    "interventionNames": [
                        "Drug: EPI-7386 with Enzalutamide"
                    ]
                },
                {
                    "label": "Phase 1 Cohort 4",
                    "type": "EXPERIMENTAL",
                    "description": "RP2D mg EPI-7386 in combination of Enzalutamide160 mg",
                    "interventionNames": [
                        "Drug: EPI-7386 with Enzalutamide"
                    ]
                },
                {
                    "label": "Phase 2 Enzalutamide + EPI-7386 (Randomized 2:1)",
                    "type": "EXPERIMENTAL",
                    "description": "RP2D mg EPI-7386 in combination of Enzalutamide RP2D mg",
                    "interventionNames": [
                        "Drug: EPI-7386 with Enzalutamide"
                    ]
                },
                {
                    "label": "Phase 2 Enzalutamide single agent",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Enzalutamide 160 mg",
                    "interventionNames": [
                        "Drug: Enzalutamide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Enzalutamide",
                    "description": "Daily oral dose of enzalutamide",
                    "armGroupLabels": [
                        "Phase 2 Enzalutamide single agent"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "EPI-7386 with Enzalutamide",
                    "description": "Daily oral dose of EPI-7386 in combination of enzalutamide",
                    "armGroupLabels": [
                        "Phase 1 Cohort 1",
                        "Phase 1 Cohort 2",
                        "Phase 1 Cohort 3",
                        "Phase 1 Cohort 4",
                        "Phase 2 Enzalutamide + EPI-7386 (Randomized 2:1)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1: Incidence of Dose Limiting Toxicities",
                    "description": "Characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for AEs \\[NCI CTCAE version 5.0\\]), timing in relation to study treatment administration, seriousness, and relationship to study treatment.",
                    "timeFrame": "Baseline to End of Cycle 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Phase 1: Incidence of treatment emergent adverse events",
                    "description": "Characterized by type, frequency, severity, timing, seriousness, and relationship to study treatment.",
                    "timeFrame": "Baseline to 30 days after last dose of study drug"
                },
                {
                    "measure": "Phase 1: Incidence of laboratory abnormalities as a measure of safety and tolerability of EPI-7386",
                    "description": "Characterized by type, frequency, severity, timing, seriousness, and relationship to study treatment.",
                    "timeFrame": "Baseline to 30 days after last dose of study drug"
                },
                {
                    "measure": "Phase 1: Changes in ECOG performance status",
                    "timeFrame": "Baseline to 30 days after last dose of study drug"
                },
                {
                    "measure": "Phase 2: Proportion of subjects with a prostate-specific antigen decline of >50% (PSA50) at Week 12",
                    "timeFrame": "Baseline to Week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Males \u226518 years.\n* Histologically, pathologically, or cytologically confirmed prostate adenocarcinoma.\n* Evidence of castration-resistant prostate cancer (CRPC).\n* Presence of metastatic disease at study entry documented by 1 or more bone lesions on bone scan or by soft tissue disease observed by CT/MRI.\n* Na\u00efve to second generation anti-androgens.\n* Evidence of progressive disease defined as 1 or more Prostate Cancer Working Group 3 (PCWG3) criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Ongoing ADT with luteinizing hormone-releasing hormone (LHRH) agonist/antagonist therapy or history of bilateral orchiectomy, with castrate level testosterone.\n* Serum testosterone \u22641.73 nmol/L (50 ng/dL).\n* Subjects receiving bisphosphonates or other approved bone-targeting therapy (e.g., denosumab) must be on a stable dose for at least 28 days prior to the start of study treatment.\n* Demonstrate adequate organ function.\n\nExclusion Criteria:\n\n* Biologic anti-cancer therapy within 28 days prior to the start of study treatment.\n* Use of hormonal agents with anti-tumor activity against prostate cancer within 28 days prior to the start of study treatment.\n* Use of herbal products or alternative therapies that may decrease PSA levels or that may have hormonal anti-prostate cancer activity within 28 days prior to the start of study treatment or plans to initiate during the study.\n* Intervention with any chemotherapy, investigational agents, or other anti-cancer drugs within 28 days of the first dose of study treatment.\n* Use of radium-223 dichloride or other radioligand/radiopharmaceutical within 28 days prior to the start of study treatment.\n* Received limited-field palliative bone radiotherapy \\>5 fractions and/or any radiotherapy within 2 weeks prior to the start of study treatment.\n* Received a blood transfusion within 28 days of hematologic screening labs.\n* Known intra-cerebral disease or brain metastasis unless adequately treated and stable for the last 28 days before signing of informed consent.\n* Spinal cord compression.\n* Diagnosis of another clinically significant malignancy within the previous 3 years other than curatively treated non-melanomatous skin cancer or superficial urothelial carcinoma and other in situ or non-invasive malignancies.\n* Gastrointestinal issues affecting absorption.\n* Significant cardiovascular disease.\n* Known history of seizure or conditions that may pre-dispose them to seizure, including brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain metastases, and brain arteriovenous malformation.\n* Concurrent disease or any clinically significant abnormality.\n* Known or suspected hypersensitivity to any components of the formulation used for EPI-7386 or enzalutamide.\n* Use of strong inhibitors of CYP2C8.\n* Use of strong inducers of CYP3A.\n* Use of narrow therapeutic index sensitive CYP2C8 or sensitive substrates for CYP3A and CYP2B6.\n* Use of granulocyte colony stimulating factor within 7 days prior to screening laboratories.\n* Not a candidate for enzalutamide treatment.\n* Patients with rare hereditary problems of fructose intolerance.",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Karen Villaluna",
                    "role": "CONTACT",
                    "phone": "650-449-8400",
                    "email": "kvillaluna@essapharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Arizona Urology",
                    "status": "RECRUITING",
                    "city": "Tucson",
                    "state": "Arizona",
                    "zip": "85741",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.22174,
                        "lon": -110.92648
                    }
                },
                {
                    "facility": "Hematology Oncology Associates of the Treasure Coast",
                    "status": "RECRUITING",
                    "city": "Port Saint Lucie",
                    "state": "Florida",
                    "zip": "34952",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.29393,
                        "lon": -80.35033
                    }
                },
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Chesapeake Urology Associates",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21204",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Johns Hopkins University",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21231",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Washington University Siteman Cancer Center",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Urology Cancer Center",
                    "status": "RECRUITING",
                    "city": "Omaha",
                    "state": "Nebraska",
                    "zip": "68130",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.25626,
                        "lon": -95.94043
                    }
                },
                {
                    "facility": "Great Lakes Cancer Center",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Roswell Park Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "OHSU Knight Cancer Instititue",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Carolina Urologic Research Center",
                    "status": "RECRUITING",
                    "city": "Myrtle Beach",
                    "state": "South Carolina",
                    "zip": "29572",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.68906,
                        "lon": -78.88669
                    }
                },
                {
                    "facility": "University of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53792",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                },
                {
                    "facility": "The Canberra Hospital",
                    "status": "RECRUITING",
                    "city": "Garran",
                    "state": "Australian Capital Territory",
                    "zip": "2605",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -35.34206,
                        "lon": 149.10846
                    }
                },
                {
                    "facility": "Chris O'Brien Lifehouse",
                    "status": "RECRUITING",
                    "city": "Camperdown",
                    "state": "New South Wales",
                    "zip": "2050",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.88965,
                        "lon": 151.17642
                    }
                },
                {
                    "facility": "St. Vincent's Hospital Sydney",
                    "status": "RECRUITING",
                    "city": "Darlinghurst",
                    "state": "New South Wales",
                    "zip": "2010",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.87939,
                        "lon": 151.21925
                    }
                },
                {
                    "facility": "Eastern Health",
                    "status": "RECRUITING",
                    "city": "Box Hill",
                    "state": "Victoria",
                    "zip": "3128",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.81887,
                        "lon": 145.12545
                    }
                },
                {
                    "facility": "Tom Baker Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Calgary",
                    "state": "Alberta",
                    "zip": "T2N 4N2",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 51.05011,
                        "lon": -114.08529
                    }
                },
                {
                    "facility": "Prostate Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Calgary",
                    "state": "Alberta",
                    "zip": "T2V 1P9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 51.05011,
                        "lon": -114.08529
                    }
                },
                {
                    "facility": "Cross Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Edmonton",
                    "state": "Alberta",
                    "zip": "T6G 1Z2",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 53.55014,
                        "lon": -113.46871
                    }
                },
                {
                    "facility": "Juravinski Cancer Centre, Hamilton, ON L8V 5C2",
                    "status": "RECRUITING",
                    "city": "Hamilton",
                    "state": "Ontario",
                    "zip": "L8V 5C2",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.25011,
                        "lon": -79.84963
                    }
                },
                {
                    "facility": "Princess Margaret Cancer Center",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Centre Hospitalier de l'Universite de Montreal",
                    "status": "RECRUITING",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "zip": "H2X 0A9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Jewish General Hospital",
                    "status": "RECRUITING",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "zip": "H3T 1E2",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}